AXSM
Price
$105.44
Change
+$1.53 (+1.47%)
Updated
Jul 3 closing price
Capitalization
5.19B
36 days until earnings call
MNOV
Price
$1.25
Change
-$0.02 (-1.57%)
Updated
Jul 3 closing price
Capitalization
61.31M
32 days until earnings call
Interact to see
Advertisement

AXSM vs MNOV

Header iconAXSM vs MNOV Comparison
Open Charts AXSM vs MNOVBanner chart's image
Axsome Therapeutics
Price$105.44
Change+$1.53 (+1.47%)
Volume$245.79K
Capitalization5.19B
Medicinova
Price$1.25
Change-$0.02 (-1.57%)
Volume$68.35K
Capitalization61.31M
AXSM vs MNOV Comparison Chart in %
Loading...
AXSM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MNOV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AXSM vs. MNOV commentary
Jul 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AXSM is a Hold and MNOV is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 07, 2025
Stock price -- (AXSM: $105.44 vs. MNOV: $1.25)
Brand notoriety: AXSM and MNOV are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AXSM: 39% vs. MNOV: 509%
Market capitalization -- AXSM: $5.19B vs. MNOV: $61.31M
AXSM [@Biotechnology] is valued at $5.19B. MNOV’s [@Biotechnology] market capitalization is $61.31M. The market cap for tickers in the [@Biotechnology] industry ranges from $316.35B to $0. The average market capitalization across the [@Biotechnology] industry is $2.38B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AXSM’s FA Score shows that 0 FA rating(s) are green whileMNOV’s FA Score has 0 green FA rating(s).

  • AXSM’s FA Score: 0 green, 5 red.
  • MNOV’s FA Score: 0 green, 5 red.
According to our system of comparison, MNOV is a better buy in the long-term than AXSM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AXSM’s TA Score shows that 4 TA indicator(s) are bullish while MNOV’s TA Score has 4 bullish TA indicator(s).

  • AXSM’s TA Score: 4 bullish, 4 bearish.
  • MNOV’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, AXSM is a better buy in the short-term than MNOV.

Price Growth

AXSM (@Biotechnology) experienced а +2.80% price change this week, while MNOV (@Biotechnology) price change was -3.85% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.30%. For the same industry, the average monthly price growth was +17.40%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

AXSM is expected to report earnings on Aug 11, 2025.

MNOV is expected to report earnings on Aug 08, 2025.

Industries' Descriptions

@Biotechnology (+6.30% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AXSM($5.19B) has a higher market cap than MNOV($61.3M). AXSM YTD gains are higher at: 24.619 vs. MNOV (-40.476). MNOV has higher annual earnings (EBITDA): -12.72M vs. AXSM (-262.01M). AXSM has more cash in the bank: 301M vs. MNOV (36.6M). MNOV has less debt than AXSM: MNOV (190K) vs AXSM (211M). AXSM has higher revenues than MNOV: AXSM (432M) vs MNOV (0).
AXSMMNOVAXSM / MNOV
Capitalization5.19B61.3M8,468%
EBITDA-262.01M-12.72M2,060%
Gain YTD24.619-40.476-61%
P/E RatioN/AN/A-
Revenue432M0-
Total Cash301M36.6M822%
Total Debt211M190K111,053%
FUNDAMENTALS RATINGS
AXSM vs MNOV: Fundamental Ratings
AXSM
MNOV
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
92
Overvalued
42
Fair valued
PROFIT vs RISK RATING
1..100
66100
SMR RATING
1..100
10094
PRICE GROWTH RATING
1..100
5164
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MNOV's Valuation (42) in the Biotechnology industry is somewhat better than the same rating for AXSM (92) in the Pharmaceuticals Other industry. This means that MNOV’s stock grew somewhat faster than AXSM’s over the last 12 months.

AXSM's Profit vs Risk Rating (66) in the Pharmaceuticals Other industry is somewhat better than the same rating for MNOV (100) in the Biotechnology industry. This means that AXSM’s stock grew somewhat faster than MNOV’s over the last 12 months.

MNOV's SMR Rating (94) in the Biotechnology industry is in the same range as AXSM (100) in the Pharmaceuticals Other industry. This means that MNOV’s stock grew similarly to AXSM’s over the last 12 months.

AXSM's Price Growth Rating (51) in the Pharmaceuticals Other industry is in the same range as MNOV (64) in the Biotechnology industry. This means that AXSM’s stock grew similarly to MNOV’s over the last 12 months.

AXSM's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as MNOV (100) in the Biotechnology industry. This means that AXSM’s stock grew similarly to MNOV’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AXSMMNOV
RSI
ODDS (%)
N/A
Bullish Trend 4 days ago
67%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
79%
Bullish Trend 4 days ago
80%
Momentum
ODDS (%)
Bullish Trend 4 days ago
77%
Bearish Trend 4 days ago
80%
MACD
ODDS (%)
Bullish Trend 4 days ago
79%
Bearish Trend 4 days ago
83%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
78%
Bearish Trend 4 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
81%
Bearish Trend 4 days ago
79%
Advances
ODDS (%)
Bullish Trend 4 days ago
78%
Bullish Trend 17 days ago
71%
Declines
ODDS (%)
Bearish Trend 11 days ago
82%
Bearish Trend 11 days ago
85%
BollingerBands
ODDS (%)
N/A
Bullish Trend 4 days ago
73%
Aroon
ODDS (%)
Bearish Trend 4 days ago
67%
Bearish Trend 4 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
AXSM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MNOV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SMMYY6.340.09
+1.52%
Sumitomo Metal Mining Co., Ltd.
KTHGF0.03N/A
N/A
Kantone Holdings Ltd.
MNOIY21.95N/A
N/A
Mandarin Oriental International Ltd.
YMAIF0.07N/A
N/A
Yoma Strategic Holdings Ltd.
RNGE0.19N/A
N/A
Range Impact Inc.

AXSM and

Correlation & Price change

A.I.dvisor indicates that over the last year, AXSM has been loosely correlated with CRNX. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if AXSM jumps, then CRNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AXSM
1D Price
Change %
AXSM100%
+1.47%
CRNX - AXSM
41%
Loosely correlated
+1.22%
PLRX - AXSM
39%
Loosely correlated
+5.00%
XENE - AXSM
37%
Loosely correlated
-0.33%
IONS - AXSM
37%
Loosely correlated
-1.35%
SWTX - AXSM
36%
Loosely correlated
N/A
More

MNOV and

Correlation & Price change

A.I.dvisor tells us that MNOV and ALT have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MNOV and ALT's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MNOV
1D Price
Change %
MNOV100%
-1.57%
ALT - MNOV
29%
Poorly correlated
-2.86%
TIL - MNOV
28%
Poorly correlated
+15.50%
NEVPF - MNOV
24%
Poorly correlated
N/A
AXSM - MNOV
24%
Poorly correlated
+1.47%
XBIO - MNOV
22%
Poorly correlated
-6.09%
More